Review of the Scientific and Educational Conference “Multidisciplinary approach in hematology and oncology in the Moscow Region”. May 22, 2025

1. Verelst S.G.R., Blommestein H.M., De Groot S. et al. Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). Hemasphere 2018;2(4):e45. DOI: 10.1097/HS9.0000000000000045

2. Chari A., Rodriguez-Otero P., McCarthy H. et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol 2021;192(5):869–78. DOI: 10.1111/bjh.16980

3. Mateos M.V., Dimopoulos M.A., Cavo M. et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 2018;378(6):518–28. DOI: 10.1056/NEJMoa1714678.

4. Dimopoulos M., San Miguel J., Belch A. et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 2018;103(12):2088–96. DOI: 10.3324/haematol.2018.194282

5. Dimopoulos M.A., Lonial S., White D. et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10(9):91. DOI: 10.1038/s41408-020-00357-4

6. Martin T., Dimopoulos M.A., Mikhael J. et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J 2023;13(1):72. DOI: 10.1038/s41408-023-00797-8

7. Richardson P.G., Perrot A., San-Miguel J. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3):416–27. DOI: 10.1016/S1470-2045(22)00019-5

8. Melikyan A.L., Gilyazitdinova E.A., Subortseva I.N. et al. Systemic mastocytosis with associated hematological neoplasm of non-mast cell origin Vestnik hematologii = Bulletin of Hematology 2022;18(2): 68–9.

9. Abdulkhalikova Z.K., Barabanshchikova M.V., Baykov V.V. et al. Difficulties of primary diagnosis in patients with suspected systemic mastocytosis. Onkogematologiya = Oncohematology 2024;19(3):142–8. (In Russ.). DOI: 10.17650/1818-8346-2024-19-3-142-148

10. Kumar A., Roberts D., Wood K.E. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589–96. DOI: 10.1097/01.CCM.0000217961.75225.E9.

11. Al-Samkari H., Kolb-Sielecki J., Safina S.Z. et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with nonhaematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2022;9(3):e179–e89. DOI: 10.1016/S2352-3026(22)00001-1

12. Anker S.D. Kirwan B.A., van Veldhuisen D.J. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in irondeficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20(1):125–33. DOI: 10.1002/ejhf.823

13. Ahmed M., Shafiq A., Javaid H. et al. Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials ESC Heart Fail 2025;12(1):43–53.

14. Lam C.S.P., Doehner W., Comin-Colet J.; IRON CORE Group. Iron deficiency in chronic heart failure: case-based practical guidance. ESC Heart Failure 2018;5(5):764–71. DOI: 10.1002/ehf2.12333.

15. Lee S.D., Park J.W., Park K.S. et al. Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis 2009;24(12):1451–8. DOI: 10.1007/s00384-009-0762-7

16. Pessôa R.L., Kessler V.G., Becker G.G. et al. Efficacy and safety of direct oral anticoagulants for acute treatment of venous thromboembolism in older adults: a network meta-analysis of randomised controlled trials. Vasc Endovascular Surg 2024;58(6):633–9. DOI: 10.1177/15385744241253201

17. Fredman D., McNeil R., Eldar O. et al. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. J Thromb Thrombolysis 2024;57(3):453–65. DOI: 10.1007/s11239-023-02926-3